| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GP1BA |
| Uniprot No | BC027955 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-531aa |
| 氨基酸序列 | HPICEVSKVASHLEVNCDKRNLTALPPDLPKDTTILHLSENLLYTFSLATLMPYTRLTQLNLDRCELTKLQVDGTLPVLGTLDLSHNQLQSLPLLGQTLPALTVLDVSFNRLTSLPLGALRGLGELQELYLKGNELKTLPPGLLTPTPKLEKLSLANNNLTELPAGLLNGLENLDTLLLQENSLYTIPKGFFGSHLLPFAFLHGNPWLCNCEILYFRRWLQDNAENVYVWKQGVDVKAMTSNVASVQCDNSDKFPVYKYPGKGCPTLGDEGDTDLYDYYPEEDTEGDKVRATRTVVKFPTKAHTTPWGLFYSWSTASLDSQMPSSLHPTQESTKEQTTFPPRWTPNFTLHMESITFSKTPKSTTEPTPSPTTSEPVPEPAPNMTTLEPTPSPTTPEPTSEPAPSPTTPEPTPIPTIATSPTILVSATSLITPKSTFLTTTKPVSLLESTKKTIPELDQPPKLRGVLQGHLESSRNDPFLHPDFCCLLPLGFYVLGLFWLLFASVVLILLLSWVGH |
| 预测分子量 | 58.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GP1BA重组蛋白的3篇文献示例(内容为模拟虚构，仅供参考)：
1. **《重组GP1BA蛋白在血小板功能研究中的应用》**
*作者：Chen L, et al.*
摘要：研究通过大肠杆菌表达系统成功获得高纯度重组GP1BA蛋白，并验证其与血管性血友病因子(vWF)的相互作用，为血小板黏附机制研究提供工具。
2. **《GP1BA基因突变体重组蛋白的构效分析》**
*作者：Wang Y, et al.*
摘要：通过哺乳动物细胞表达系统构建多个GP1BA突变体重组蛋白，解析其结构变化对血小板活化信号传导的影响，揭示Bernard-Soulier综合征致病机理。
3. **《基于重组GP1BA蛋白的免疫诊断试剂开发》**
*作者：Zhang R, et al.*
摘要：利用昆虫细胞表达的重组GP1BA蛋白开发ELISA检测试剂，用于快速筛查自身免疫性血小板减少症患者血清中的特异性抗体。
4. **《CRISPR编辑联合重组GP1BA的基因治疗研究》**
*作者：Kimura T, et al.*
摘要：探索重组GP1BA蛋白作为基因治疗载体靶向递送CRISPR系统，修复遗传性血小板功能障碍模型小鼠的GP1BA基因缺陷。
(注：以上文献信息为示例性质，实际文献需通过PubMed等学术平台检索获取。)
**Background of GP1BA Recombinant Protein**
Glycoprotein Ib alpha (GP1BA), a critical subunit of the platelet glycoprotein Ib-IX-V (GPIb-IX-V) complex, plays a central role in primary hemostasis and thrombus formation. Located on the surface of platelets, GP1BA mediates the initial adhesion of platelets to von Willebrand factor (vWF) at sites of vascular injury, particularly under high shear stress conditions. This interaction triggers platelet activation, signaling cascades, and subsequent thrombus stabilization. Structurally, GP1BA consists of an extracellular N-terminal ligand-binding domain, a leucine-rich repeat region, and a cytoplasmic tail involved in intracellular signaling.
The recombinant GP1BA protein is engineered to mimic the native protein's functional properties, typically produced using mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications, such as glycosylation. Its production enables detailed studies of platelet biology, vWF interactions, and pathological mechanisms underlying thrombotic disorders (e.g., arterial thrombosis) or bleeding disorders like Bernard-Soulier syndrome, caused by GP1BA mutations.
In research, recombinant GP1BA serves as a tool to investigate inhibitor development for antithrombotic therapies, diagnose platelet-related disorders, or study autoimmune responses in immune thrombocytopenia. Additionally, it aids in structural analyses to map binding epitopes for therapeutic antibodies or small molecules. Future applications may include its use as a targeted drug carrier or in gene therapy approaches to correct genetic defects. Overall, GP1BA recombinant protein bridges fundamental platelet biology with translational clinical innovations.
×
